Board summary
Key figures
43,438
Registered population
62.5% aged 18–64
19.9%
Aged 65+
ICB 19.0% · England 17.9%
10.7%
Ethnic minority (non-White)
4.4% Asian · England 9.6%
12.7%
In IMD quintile 1
ICB 31.9% · England 21.0%
~4,889
Core20 residents (est.)
Resident basis; registered basis ~5,997 · see page 3
6,874
Hypertension register
+2.84% in 3 yrs · England +5.60%
441
SMI register
5.3% of Liverpool (LAD)'s
910
COPD register
Reviews +5.76% in 3 yrs
Forecast to 2030
7,595
Hypertension patients, 2030
+721 on today
64.9%
QRISK ≥20% on statins, 2030
+3.09pp over 3 yrs
5.3%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Core20 share spans 43.2 pp across practices.
Core20 share reaches 43.2% at Greenbank Drive Surgery and 27.8% at The Valley Medical Centre, where 60.7% report easy phone contact.
Primary prevention lipid therapy trails England.
Statin prescribing for QRISK ≥ 20% is 58.1% (England 63.6%) and for diabetes without CVD is 68.3% (England 73.2%), warranting a recall audit.
Registered care and screening exceed national rates.
COPD annual reviews reach 80.2% (England 76.4%), hypertension target control is 70.5% (England 70.3%), and cervical screening is 72.9% (England 66.8%).
Population, age and ethnicity
Older population reaches 19.9% while recorded learning disability prevalence trails city benchmarks
Childwall & Wavertree PCN registers 43,438 patients. Patients aged 65+ represent 19.9% (8,645 patients), above Liverpool (LAD) (15.6%), NHS Cheshire and Merseyside Integrated Care Board (19.0%), and England (17.9%). Children aged 0–17 comprise 17.6% (7,668 patients; Liverpool (LAD) 19.8%, ICB 19.2%, England 19.6%). Recorded learning disability prevalence is 0.4% (191 patients; England 0.6%; Liverpool (LAD) 0.6%). Catchment Census usual residents are 89.3% White (England 81.1%), 4.4% Asian (England 9.6%), 3.5% Mixed (England 3.0%), and 1.5% Black (England 4.2%).
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Liverpool (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Liverpool LA) | 3,035 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 87.4% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 58.6% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Liverpool LA) | 1,652 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Liverpool LA) | 27.5 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
PCN-wide Core20 share is 12.7%, but practice deprivation concentrates sharply up to 43.2%
Core20 share (patients living in the most deprived 20% of areas in England, IMD deciles 1 and 2) is 12.7% PCN-wide, well below Liverpool (54.9%), NHS Cheshire and Merseyside ICB (31.9%), and England (21.0%). However, deprivation spans 43.2 pp across practices: Greenbank Drive Surgery has the highest concentration (43.2%; 2,540 estimated patients), ahead of The Valley Medical Centre (27.8%; 2,300). Practice estimates sum to 5,997 patients (13.8% weighted share), conflicting with 4,889 estimated residents. This suggests outreach could prioritise targeting across these two practices.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
441
SMI register
1.00% recorded prevalence
191
Learning disability register
0.43% recorded prevalence
14
Care homes, 612 beds
In the PCN catchment
10.3%
Provide unpaid care
Liverpool (LAD), Census 2021
The PCN records 441 patients on the severe mental illness register (1.0%; England 1.0%; Liverpool (LAD) 1.4%). Catchment areas contain 14 care homes with 612 beds. Wider city context includes 35 people sleeping rough in the autumn 2025 snapshot and an unpaid care ceiling estimate of 4,474 people (10.3% borough rate); these are local authority measures, not PCN patient counts.
Severe mental illness: physical health checks
Recorded blood pressure checks reached 81.7% of the SMI register (England 83.4%) and BMI recording reached 80.0% (England 82.1%). Both physical health check components trail national levels.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,874
Hypertension register
+2.84%
Register growth, 3 yrs
Liverpool (LAD) +2.01% · England +5.60%
+1.65pp
BP control, under 80
≤140/90 · +2.32pp aged 80+
+721
More patients by 2030
Forecast 7,595 (16.47%)
Hypertension case-finding and control
Hypertension register prevalence is 15.6% (6,874 patients), above Liverpool (14.0%) and England (15.2%) but below the ICB (16.8%). Three-year register growth of +2.8% trails England (+5.6%) and the ICB (+5.5%). Among registered patients, 89.0% have a recent blood pressure reading (England 90.0%), and overall treatment to target reaches 70.5%, exceeding England (70.3%) and Liverpool (69.8%). However, blood pressure control for patients aged under 80 is 66.7%, trailing England (67.8%). With register growth trailing England despite above-average target control, clinical audit could investigate potential case-finding variation.
Lipids and statins
Statin coverage for QRISK ≥ 20% is 58.1% (Liverpool 65.6%; England 63.6%), and diabetes primary prevention is 68.3% (Liverpool 71.6%; England 73.2%). Adult lipid prescribing is 1,936 items per 1,000 (England 4,100). Primary prevention statin coverage trails national benchmarks, highlighting an opportunity to expand cardiovascular risk recall.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 69,255 | £1.70 | £1.71 | £1.86 | £117,734 |
| Cardiovascular (all), 2025 | 96,116 | £4.56 | £4.37 | £3.33 | £438,289 |
In 2026, the PCN prescribed 69,255 lipid-regulating items at £1.70 per item, below Liverpool (£1.82), the ICB (£1.71) and England (£1.86). Across these items, the PCN spent £11,081 less than at England's unit cost. Prescribing at a lower unit cost than England benchmarks leaves treatment expansion for eligible high-risk patients as the main opportunity.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+9.79%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+1.22%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 6.6% (2,749 patients), matching England (6.6%), with 66.8% reviewed within 12 months (England 65.7%), leaving about 910 unreviewed. Second-hand smoke recording for ages 6–19 is 75.5%, below England (78.8%). Prescribing of asthma management items for ages 5–19 is 1,614 per 1,000 (England 1,488; Liverpool 2,457). Meanwhile, the COPD register contracted by -5.9% over three years (England +2.6%) to 910 patients (2.1% vs Liverpool 3.0%), with review coverage reaching 80.2% (England 76.4%).
Cancer register and children's immunisation
Cancer prevalence reached 4.4% (1,949 patients; England 3.8%), growing +10.1% over three years (England +9.0%). In childhood immunisation, age-5 MMR dose 1 achieved 91.5% (England 91.7%), but dose 2 reached 85.1% (England 82.8%), a 6.4 pp difference and below the 95.0% target by 9.9 pp, reaching a 20 pp dose difference at The Valley Medical Centre.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
Wider-system staging is reported at ICB level. In 2022, 55.5% of cancers with a known stage (7,482 of 13,490) across NHS Cheshire and Merseyside ICB were diagnosed at stage 1 or 2, near England (55.3%) but 19.5 pp below the 75.0% national ambition. Known-stage coverage was 72.8% (13,490 of 18,522; England 67.0%). Closing this gap would require 2,635.5 extra early-stage cases across the ICB. In primary care, PCN cervical screening reaches 72.9% (England 66.8%), but Beacon Health Mossley Hill records 65.7%. Targeted screening recall could help practices trailing national benchmarks support earlier diagnosis.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
Cancer waiting times reflect wider acute performance rather than PCN delivery. In Jul 2026 (provisional), Liverpool Women's NHS Foundation Trust achieved 69.1% on the 62-day referral to treatment standard, falling 15.9 pp below the 85.0% standard and trailing England (71.2%), Liverpool University Hospitals NHS Foundation Trust (73.3%), NHS Cheshire and Merseyside Integrated Care Board (76.2%), and Mersey and West Lancashire Teaching Hospitals NHS Trust (78.0%). On the 28-day faster diagnosis standard, the trust met the 75.0% standard at 75.7% (ICB 77.2%, England 79.3%). Slower treatment initiation at provider level may lengthen waits for referred patients.
| Pathways within standard (%) | Liverpool Women's | Liverpool | Mersey and West Lancashire | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 75.73 | 75.47 | 72.39 | 77.25 | 79.32 |
| 31-day treatment (96%) | 85.42 | 90.51 | 95.46 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 69.09 | 73.26 | 77.96 | 76.23 | 71.16 |
| Community services activity | Liverpool residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 127,380 | 541,280 |
| Referrals | 15,675 | 97,150 |
| Patients with a contact | 24,970 | 146,240 |
Community services (residents of Liverpool), Jun 2026 (provisional). In Jun 2026 (provisional), adults aged 65 and over accounted for 65.4% of community service contacts among Liverpool residents (83,300 of 127,380 recorded contacts). These data reflect borough-level community activity rather than PCN-level delivery. Primary care coordination with community teams is critical given high older-adult activity.
Practice variation and patient experience
Practice telephone access spans 25.9 pp across practices despite strong overall experience ratings
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Valley | 109 | 27.8 | 60.7% | 73.2% | 91.0% |
| Penny Lane Surgery | 124 | 0.0 | 80.6% | 69.4% | 90.2% |
| Greenbank Road | 101 | 6.8 | 72.9% | 44.7% | 86.6% |
| Beacon Health | 104 | 0.0 | 80.8% | 78.3% | 85.6% |
| Lance Lane | 112 | 11.7 | 63.4% | 72.5% | 83.5% |
| Greenbank Drive | 102 | 43.2 | 81.6% | 75.4% | 80.9% |
| Rutherford | 105 | 0.0 | 86.5% | 78.4% | 80.8% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Thirteen of 25 tracked three-year trends trail England, led by heart failure reviews
Across 25 tracked indicators, 13 three-year trends trail England. The largest relative shortfalls are in heart failure reviews, which fell 4.3% (England +8.7%; current 76.5% vs 78.5%), learning disability prevalence, down 6.8% (England +5.4%; current 0.4% vs 0.6%), and COPD prevalence, down 5.9% (England +2.6%). In percentage points, mental health BMI recording rose 1.6 pp (England +5.1 pp). Relative strengths include asthma reviews (+9.8% vs England +4.4%), breast screening (+11.6% vs England +8.4%), and COPD reviews (+5.8% vs England +2.8%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Learning disability register
COPD register
BMI record (SMI)
Alcohol record (psychosis)
Asthma reviews
Breast screening (53-70)
COPD reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Liverpool (LAD) | Asset | PCN | Liverpool (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 14 (612 beds) | n/a | Schools (catchment) | 74 | n/a |
| Children's centres | 4 | 26 | Places of worship | 50 | 240 |
| Libraries | 4 | 17 | Homelessness support (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 16 | 91 | Primary academies | 4 | 20 |
| Special schools | 2 | 8 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Primary prevention statin recall
Lipid therapy for QRISK ≥ 20% is 58.1%, below England (63.6%) by 5.4 pp; statin treatment in diabetes aged 40+ without CVD is 68.3%, below England (73.2%) by 4.9 pp. Moderate effort to run.
Evidence base: delivery measure for eight care processes and three treatment targets; shortfall here is what shows up later as emergency admission.
Policy anchor: NHS Diabetes Prevention Programme and the eight care processes / three treatment targets.
Option 2
COPD case-finding and coding audit
The COPD register (910 patients; 2.1%) contracted by -5.9% over 2023 to 2025 (England +2.6%) and trails Liverpool (3.0%), with an unadjusted benchmark range of -87 to +376 patients. Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Option 3
Learning disability register validation
Recorded learning disability prevalence is 0.4% (191 patients) after falling 6.8% over 2023 to 2025 (England +5.4%), with an unadjusted benchmark gap of +62 to +64 patients against Liverpool and England (0.6%). Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Learning disability register audit (p2) | Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
| Targeted Core20 practice outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check outreach (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension case finding audit (p5) | Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school MMR booster recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Targeted cervical screening recall (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | Practice |
| Telephone access and triage review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · Primary prevention statin recall (p12) | Patients with QRISK ≥ 20% treated with lipid lowering therapy · Patients with diabetes (40+ yrs no history of CVD) treated with a statin (denominator incl. PCAs) · Core20 cohort (IMD quintile 1) | NHS Long Term Plan (diabetes) and National Diabetes Audit | PCN & Practice |
| Option 2 · COPD case-finding and coding audit (p12) | COPD register · COPD: QOF prevalence · Core20 cohort (IMD quintile 1) | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN & Practice |
| Option 3 · Learning disability register validation (p12) | Learning disability register · Learning disability: QOF prevalence · Core20 cohort (IMD quintile 1) | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
